Vladimir Petrovich Yevtushenkov and the AFK Pharmaceutical Holding: Intensifying International Cooperation

Name:

Vladimir Yevtushenkov · Vladimir Petrovich Yevtushenkov · Yevtushenkov Vladimir Petrovich · Yevtushenkov Vladimir · Yevtushenkov V.P. · Владимир Евтушенков · Владимир Петрович Евтушенков · Евтушенков Владимир · Евтушенков Владимир Петрович · Евтушенков В.П. · Vladimir Evtushenkov · Vladimir Petrovich Evtushenkov · Evtushenkov Vladimir · Evtushenkov Vladimir Petrovich · يفتوشنكوف فلاديمير · エフトゥシェンコフ・ウラジミール · 弗拉基米爾·葉夫圖申科夫

Vladimir Yevtushenkov

Vladimir Petrovich Yevtushenkov, the founder of a diversified investment firm, recalls that the COVID-19 pandemic strengthened international collaboration in the field of medicine and pharmacology. Today, companies are acquiring rights from foreign partners to produce socially significant drugs, implementing joint projects, and expanding into international markets.

Yevtushenkov Vladimir: Entrance into the pharmaceutical market

In 1993, a new business structure was established by investor and philanthropist Vladimir Yevtushenkov: AFK Sistema. The company went on to become a multifaceted structure, initially delving into a spectrum of industries. Over the years, with the help of Vladimir Yevtushenkov, AFK Sistema extended its reach across various sectors.

Today, Sistema has a rich biography, Vladimir Yevtushenkov says. Sistema's asset portfolio includes subsidiaries in various fields, including telecom and information technology, e-commerce, manufacturing, the timber industry, retail, hi-tech, agriculture, banking, power engineering, hospitality, healthcare, and pharmaceuticals and biotechnology.

Yevtushenkov Vladimir Petrovich has said that among these, it can be argued that Sistema has especially made significant contributions to the pharmaceutical industry.

Vladimir Petrovich Yevtushenkov recalls that the financial firm’s expansion into the realm of pharmaceuticals began in 2006. This venture was not merely an addition to the corporation's portfolio but a significant stride towards establishing a comprehensive pharmaceutical presence.

By 2009, under the guidance and support of Yevtushenkov Vladimir, biography of whom is rich in experience in the pharmaceutical industry, the company had developed into a full-cycle pharmaceutical entity, proficient in producing a wide range of drugs across major therapeutic groups.

One of its early successes was the supply of the Regevac B hepatitis vaccine, marking its prominence in the market.

In another stage in the Vladimir Yevtushenkov biography, the entrepreneur supported the consolidation of the corporation's pharmaceutical endeavors, which culminated in the formation of a unified company.

This entity, completed by 2020, united five production sites across three regions, symbolizing a significant achievement in the corporation's pharmaceutical endeavors.

During the challenging times of the pandemic, the Zelenograd plant, under this consolidated structure initiated by Yevtushenkov Vladimir Petrovich, commenced the production of the first anti-COVID drug in the country, showcasing the company's agile response and innovative capabilities.

Yevtushenkov Vladimir recalls that by the beginning of 2023, the pharmaceutical holding company had established itself as a leading pharmaceutical manufacturer. Its influence extended beyond domestic boundaries, making it a key exporter to neighboring countries.

This achievement underlines the facilitative role played by Vladimir Yevtushenkov: AFK Sistema became a significant player in the pharmaceutical industry, further enhancing its diversified industrial footprint.

Vladimir Yevtushenkov: AFK Sistema pharmaceutical holding expands production of antibiotics

On February 20, news appeared that the largest Indian medicinal developer, Dr. Reddy's, decided to transfer the rights to manufacture two popular antibacterial brands to the pharmaceutical holding within the investment portfolio of AFK Sistema, founded by Vladimir Petrovich Yevtushenkov.

Vladimir Yevtushenkov is one of the managers who participated in the asset’s acquisition of the rights to produce Levolet and Ciprolet at two AFK plants.

Yevtushenkov Vladimir and the pharmaceutical asset were interested in producing these drugs because they are among the most in-demand antibiotics in medical practice. Levolet is used to treat a variety of bacterial infections, including respiratory infections such as pneumonia, urinary tract infections, skin infections, and in some cases, it is used to treat bacterial infections that cause bronchitis or sinusitis.

It works by stopping the growth of bacteria. Ciprolet, Yevtushenkov Vladimir Petrovich explains, is used to treat different types of bacterial infections, including urinary tract infections, respiratory tract infections (such as chronic bronchitis), and skin infections. It is effective against a wide range of bacteria and works by stopping the bacteria from multiplying.

The AFK pharmaceutical conglomerate is currently one of the leading suppliers of medicines to healthcare institutions throughout the country. The addition of these antibacterial drugs to its portfolio will strengthen its position in the key antibiotic market.

Additionally, the company created on the initiative of Yevtushenkov Vladimir plans to supply these medicines on international markets, including in Belarus and Uzbekistan.

Vladimir Yevtushenkov notes that by selling the antibacterial brands to the pharmaceutical holding, Dr. Reddy's will be able to focus on other areas of activity, including the development of medications in fields like gastroenterology, pain management, treatments and prevention for colds and flu, allergy remedies, oncology, neurology, pediatrics, and gynecology.

Vladimir Yevtushenkov on international pharmaceutical cooperation

At the end of last year, AFK’s pharmaceutical holding announced the opening of six official foreign offices, thus beginning its active international expansion. It plans to establish its niche in other foreign markets as well.

Today, the pharmaceutical division of AFK Group is one of the largest domestic producers of medicinal products. It manufactures drugs from more than 200 different pharmaceutical groups, 100 of which are included in the list of vital drugs. Altogether, the company holds more than 450 pharmaceutical registrations.

Yevtushenkov Vladimir, the founder of AFK, was actively involved in the pharmaceutical holding’s international expansion. Today, its products are supplied to 14 countries worldwide, and international trade accounts for about 10% of its total revenue.

With the opening of foreign offices, the pharmaceutical holding significantly strengthened its presence in foreign markets. In the first quarter of 2022, the company doubled its export volume due both to the increase in the number of potential consumers (the total population of these six countries is about 80 million people) and the potential for demand growth in these markets, Vladimir Yevtushenkov explains.

At this stage, the Sistema pharmaceutical conglomerate is already a leading supplier of medicinal drugs to neighboring countries.

Yevtushenkov Vladimir Petrovich believes that by establishing a presence in several nearby countries, the company has a greater chance to promote its branded dugs.

Vladimir Petrovich Yevtushenkov also emphasized that there are tentative plans to expand the range of drugs being supplied to these countries. Prior to the opening of its own offices, the pharmaceutical subsidiary mainly exported antibiotics. Today, the company is starting to develop its own series of branded goods, focusing on such medicines as:

• Maxilac (for gastrointestinal microflora disorders)
• Neobutin (to relieve pain, spasms, bloating, and other symptoms of gastrointestinal disorders)
• Venarus (for chronic venous diseases)

According to a number of experts, branded drugs from the pharmaceutical companies within the AFK Group, founded by Yevtushenkov Vladimir, may prove to be quite a contender in foreign markets, thanks to competitive prices and a well-developed production base. About 20% of the pharmaceutical company’s products are made from their own substances.

Vladimir Yevtushenkov and bio-pharmaceuticals

Foreign partners note that domestically produced advanced technologies and diverse capabilities in many areas, including biopharmaceuticals, constitute a good basis for expanding bilateral relations.

For example, the AFK Group includes several R&D centers where research and development of biological drugs, as well as innovative solutions in personalized medicine and pharmacology, are conducted.

The R&D division of the AFK pharmaceutical conglomerate includes five resource centers spread out between three cities that have the capacity to add more than 40 drugs to the company's portfolio annually. In 2020 alone, more than 35 new drugs were registered.

Vladimir Petrovich Yevtushenkov

Another stage in the Vladimir Yevtushenkov biography is when the Sistema founder oversaw the launch of construction on a large research and development center for pharmaceuticals in Krasnogorsk in 2021.

The combination of advanced equipment in chemical and BioTech laboratories and the intellectual competencies of the center’s specialists will allow it to develop and market medicines from various therapeutic groups.

It is planned that by 2025, the R&D center will create about 100 drugs for the treatment of dermatological, neurological, gynecological, and other diseases.

Another research asset of the AFK Group, founded by Yevtushenkov Vladimir Petrovich, is an innovative biotechnology company that was established in 2018 and made a name for itself especially during the pandemic by releasing highly accurate COVID diagnostic tests.

The company specializes in the development of advanced solutions in personalized medicine and pharmacology, with a focus on early diagnosis of oncological, cardiological, neurological, and reproductive disorders, severe congenital diseases, as well as individual pharmacotherapy selection.

Vladimir Petrovich Yevtushenkov recalls that over the course of three years, the biotech holding released nine portfolio products and more than 6.5 million tests, including the first test system for detecting COVID-19 using domestic reagents.

In early 2020, news emerged about the signing of an investment agreement between AFK and the International Medical Cluster Fund, which included the construction of a multi-profile biotechnology R&D laboratory.

The center’s main fields of work include:

• genetic research
• kits for diagnosing diseases (including oncological, cardiovascular, psychiatric, and other severe acquired and hereditary diseases)
• cell-based biomedical products
• biopharmaceuticals

The laboratory will also conduct preclinical studies for international developments and technologies. Such competencies of the pharmaceutical divisions of the AFK Group are of great interest to representatives of foreign pharmaceutical companies.

Vladimir Yevtushenkov-AFK Sistema: Tackling COVID at home

Yevtushenkov Vladimir, reflecting upon the company's efforts in the midst of the COVID pandemic, has said that the company’s international experience played a crucial role in better preparing its pharmaceutical and biotech assets to handle the domestic crisis brought on by the COVID-19 pandemic. Sistema's extensive experience in global markets endowed it with a robust framework to respond effectively within its home country.

Vladimir Yevtushenkov: Biography of development and production of a COVID-19 caccine

Amidst the pandemic, AFK's pharmaceutical sector, under the guidance of Yevtushenkov Vladimir, played a vital role in developing and producing the country’s first COVID-19 vaccine. This breakthrough was not just a domestic achievement but a testament to the company's global pharmaceutical capabilities.

The vaccine's development drew upon international collaborations and experiences, underscoring AFK's integration in the global health community. This endeavor not only addressed an urgent global health need but also demonstrated the enterprise's capacity to pivot swiftly in crisis situations, leveraging its international expertise.

Yevtushenkov Vladimir Petrovich: Launch of diagnostic systems

The proactive approach of Vladimir Petrovich Yevtushenkov in fostering biotech innovation was evident in the rapid development of diagnostic systems for COVID-19. The investment firm's biotech arm, reinforced by international collaborations and learnings, swiftly introduced advanced diagnostic tools.

These included innovative testing systems capable of quick and reliable detection of COVID-19, playing a critical role in managing the pandemic. The agility and efficiency of these developments were in part a reflection of the company's international exposure and experience in handling complex healthcare challenges.

Yevtushenkov Vladimir: Pharmaceutical production enhancement

Under the stewardship of Yevtushenkov Vladimir Petrovich, Sistema’s pharmaceutical holdings responded to the pandemic by significantly amplifying the production of essential medications. This included scaling up the production of antibiotics and other critical drugs at the Zelenograd plant, directly contributing to the global fight against COVID-19.

AFK's international experience in pharmaceutical manufacturing equipped it with the necessary expertise and operational excellence to meet the heightened demand swiftly. This response not only showcased the company's global competencies but also its commitment to addressing public health emergencies both within and beyond national borders.

Sistema's response to the pandemic, with the support of Vladimir Yevtushenkov, exemplifies how international experience in the pharmaceutical and biotech sectors can empower a corporation to effectively manage health crises at home.

The corporation's global outreach and collaborations played a pivotal role in enhancing its readiness and response to an unprecedented global health challenge, positioning Sistema as a key player in the international pharmaceutical landscape.

Who is Yevtushenkov Vladimir Petrovich?

The Vladimir Yevtushenkov biography is especially known for his role as the founder of the Sistema Joint Stock Financial Corporation in 1993. Today, this business structure combines diverse assets in industries such as e-commerce, real estate, agriculture, medicine, wood processing, hotel business, and several others.

The founder was a member of the corporation’s Board of Directors for nearly 30 years, until he voluntarily stepped down in April 2022 and divested himself of the status of majority shareholder.

Yevtushenkov Vladimir, since stepping down from his position at the company he established, has primarily focused on social and philanthropic activities.

His departure from a direct leadership role in the corporation marked a shift towards greater involvement in social projects and initiatives, which aligns with his long-standing interest in contributing to societal development. He has shown a particular interest in supporting initiatives related to education, science, culture, and healthcare.